Tag

Ocugen

All articles tagged with #ocugen

healthcare3 days ago•2 min saved

Ocugen’s GA gene therapy shows potential edge over rivals in early phase 2 data

Ocugen reports preliminary phase 2 data for OCU410 to treat geographic atrophy (GA) from dry AMD, with the medium dose showing a 54% reduction in lesion growth vs placebo at 12 months and the high dose 36% in a small patient subset, raising questions about dose response; Ocugen aims to present full data this quarter and move to phase 3 by year-end, targeting an FDA filing in 2028, and argues the therapy could outperform Apellis' Syfovre and Astellas' Izervay.

via Fierce Biotech|

#apellis #geographic-atrophy #healthcare

health-and-biotechnology1 year ago•4 min saved

"Ocugen, Inc. Completes Dosing for Phase 1/2 Trial of OCU410 for Geographic Atrophy"

Ocugen, Inc. completes dosing in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a gene therapy candidate for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD). The trial aims to assess the safety and efficacy of OCU410, which targets multiple pathways causing dAMD, including complement, lipid metabolism, inflammation, and oxidative stress. The company is optimistic about the potential of OCU410 as a one-time treatment for GA and plans to continue providing clinical updates as the trial progresses.

via Yahoo Finance|

#clinical-trial #gene-therapy #geographic-atrophy

health-and-medicine1 year ago•4 min saved

"Ocugen Completes Dosing for Stargardt Clinical Trial Phase 1/2"

Ocugen, Inc. has completed dosing in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST, a potential gene therapy for Stargardt disease, a genetic eye disorder causing retinal degeneration and vision loss. The trial aims to assess the safety and efficacy of OCU410ST, which utilizes an AAV delivery platform for retinal delivery of the RORA gene. The company's Chief Scientific Officer, Dr. Arun Upadhyay, highlighted the significance of this milestone in providing hope for patients with Stargardt disease, for which there is currently no treatment option available.

via Yahoo Finance|

#clinical-trial #gene-therapy #health-and-medicine